Welcome to our dedicated page for HUTCHMED (China) SEC filings (Ticker: HMDCF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
HUTCHMED (China) Limited filings document foreign private issuer reporting through Form 6-K submissions, annual report materials, annual general meeting notices, circulars, proxy forms and depositary voting instructions for holders of American depositary shares. The disclosures identify HUTCHMED as a commercial-stage biopharmaceutical company developing targeted therapies and immunotherapies for cancer and immunological diseases.
Its regulatory documents also cover total voting rights, ordinary share and ADS equivalence, shareholder voting mechanics, governance materials and company announcements on drug-development programs such as sovleplenib and HUTCHMED-discovered oncology compounds.
HUTCHMED (China) Limited is sharing a broad set of oncology clinical data at the 2026 ASCO Annual Meeting in Chicago. The centerpiece is a pivotal Phase II registration study of savolitinib in MET-amplified gastric or gastroesophageal junction cancer in China.
The savolitinib study met its primary endpoint, with an Independent Review Committee–assessed objective response rate of 32.3% as of October 8, 2025, exceeding a pre-specified efficacy threshold. Disease control rate was 63.1%, median time to response 1.4 months, duration of response 9.7 months, and progression-free survival 4.0 months. These data supported a New Drug Application in China that was accepted and granted priority review.
The company will also present further analyses from its fruquintinib FRESCO, FRESCO-2, FRUSICA-1 and FRUSICA-2 studies, plus numerous investigator-initiated studies of fruquintinib and surufatinib across colorectal, gastric, renal, gynecologic, hepatobiliary, pancreatic, lung and other tumor types, highlighting the breadth of its clinical development program.
HUTCHMED (China) Limited is sharing a broad set of oncology clinical data at the 2026 ASCO Annual Meeting in Chicago. The centerpiece is a pivotal Phase II registration study of savolitinib in MET-amplified gastric or gastroesophageal junction cancer in China.
The savolitinib study met its primary endpoint, with an Independent Review Committee–assessed objective response rate of 32.3% as of October 8, 2025, exceeding a pre-specified efficacy threshold. Disease control rate was 63.1%, median time to response 1.4 months, duration of response 9.7 months, and progression-free survival 4.0 months. These data supported a New Drug Application in China that was accepted and granted priority review.
The company will also present further analyses from its fruquintinib FRESCO, FRESCO-2, FRUSICA-1 and FRUSICA-2 studies, plus numerous investigator-initiated studies of fruquintinib and surufatinib across colorectal, gastric, renal, gynecologic, hepatobiliary, pancreatic, lung and other tumor types, highlighting the breadth of its clinical development program.
HUTCHMED (China) Limited reports that China’s NMPA has approved ELUNATE (fruquintinib) plus TYVYT (sintilimab injection) for patients with locally advanced or metastatic renal cell carcinoma after VEGFR-TKI therapy and without prior PD-1/PD-L1 treatment in first line.
The approval is based on the Phase III FRUSICA-2 study, where the combination reduced the risk of disease progression or death by 63% and achieved a median progression free survival of 22.2 months versus 6.9 months on axitinib or everolimus. Objective response rate was 60.5% compared with 24.3%, and median duration of response reached 23.7 months versus 11.3 months. Safety was consistent with known profiles of each drug.
HUTCHMED (China) Limited reports that China’s NMPA has approved ELUNATE (fruquintinib) plus TYVYT (sintilimab injection) for patients with locally advanced or metastatic renal cell carcinoma after VEGFR-TKI therapy and without prior PD-1/PD-L1 treatment in first line.
The approval is based on the Phase III FRUSICA-2 study, where the combination reduced the risk of disease progression or death by 63% and achieved a median progression free survival of 22.2 months versus 6.9 months on axitinib or everolimus. Objective response rate was 60.5% compared with 24.3%, and median duration of response reached 23.7 months versus 11.3 months. Safety was consistent with known profiles of each drug.
HUTCHMED (China) Ltd director and acting CEO/CFO Cheng Chig Fung reported performance-based equity allocations under the company’s Long Term Incentive Plan. On May 20, 2026, 30,157 ordinary shares from 2024 LTIP awards and 26,307 ordinary shares from 2025 LTIP awards were allocated at a purchase price of zero. The shares are held indirectly by an LTIP trustee on his behalf and are expected to vest and transfer to his personal account in 2027 and 2028, subject to award terms. These are compensation-related restructurings rather than open-market trades.
HUTCHMED (China) Ltd director and acting CEO/CFO Cheng Chig Fung reported performance-based equity allocations under the company’s Long Term Incentive Plan. On May 20, 2026, 30,157 ordinary shares from 2024 LTIP awards and 26,307 ordinary shares from 2025 LTIP awards were allocated at a purchase price of zero. The shares are held indirectly by an LTIP trustee on his behalf and are expected to vest and transfer to his personal account in 2027 and 2028, subject to award terms. These are compensation-related restructurings rather than open-market trades.
HUTCHMED (China) Ltd Group General Counsel Charles George Rupert Nixon reported compensation-related allocations under the company’s Long Term Incentive Plan. On the reported date, 7,445 ordinary shares from awards granted on August 5, 2024 and 7,644 ordinary shares from awards granted on June 9, 2025 were allocated at a purchase price of zero.
The shares are held by the Long Term Incentive Plan trustee on his behalf and are expected to vest and transfer to his personal account in 2027 and 2028, respectively, subject to the award terms. These are indirect holdings and there were no open-market buys or sells.
HUTCHMED (China) Ltd Group General Counsel Charles George Rupert Nixon reported compensation-related allocations under the company’s Long Term Incentive Plan. On the reported date, 7,445 ordinary shares from awards granted on August 5, 2024 and 7,644 ordinary shares from awards granted on June 9, 2025 were allocated at a purchase price of zero.
The shares are held by the Long Term Incentive Plan trustee on his behalf and are expected to vest and transfer to his personal account in 2027 and 2028, respectively, subject to the award terms. These are indirect holdings and there were no open-market buys or sells.
HUTCHMED (China) Ltd director and CEO/CSO Su Wei-guo reported new allocations under the company’s Long Term Incentive Plan. On May 20, 2026, awards linked to FY2025 performance resulted in 132,864 ordinary shares from an August 5, 2024 grant and 75,140 ordinary shares from a June 9, 2025 grant being allocated at a purchase price of zero.
These shares are held by the Long Term Incentive Plan trustee on his behalf and are expected to vest, and be transferred to his personal account, in 2027 for the 2024 grant and 2028 for the 2025 grant, subject to the awards’ terms and conditions.
HUTCHMED (China) Ltd director and CEO/CSO Su Wei-guo reported new allocations under the company’s Long Term Incentive Plan. On May 20, 2026, awards linked to FY2025 performance resulted in 132,864 ordinary shares from an August 5, 2024 grant and 75,140 ordinary shares from a June 9, 2025 grant being allocated at a purchase price of zero.
These shares are held by the Long Term Incentive Plan trustee on his behalf and are expected to vest, and be transferred to his personal account, in 2027 for the 2024 grant and 2028 for the 2025 grant, subject to the awards’ terms and conditions.
HUTCHMED (China) Ltd reported a Form 4 for Deputy Chief Financial Officer Lorenso Chiu showing allocations under its Long Term Incentive Plan. On May 20, 2026, a plan trustee allocated 8,863 ordinary shares from awards granted on June 9, 2025 and 5,176 ordinary shares from awards granted on August 5, 2024, both at a purchase price of zero. These shares are held indirectly by the Long Term Incentive Plan trustee on his behalf and are expected to vest and transfer to his personal account in 2028 and 2027, respectively, subject to award terms. No open-market buys or sells were reported.
HUTCHMED (China) Ltd reported a Form 4 for Deputy Chief Financial Officer Lorenso Chiu showing allocations under its Long Term Incentive Plan. On May 20, 2026, a plan trustee allocated 8,863 ordinary shares from awards granted on June 9, 2025 and 5,176 ordinary shares from awards granted on August 5, 2024, both at a purchase price of zero. These shares are held indirectly by the Long Term Incentive Plan trustee on his behalf and are expected to vest and transfer to his personal account in 2028 and 2027, respectively, subject to award terms. No open-market buys or sells were reported.
HUTCHMED (China) Limited reports that all resolutions at its May 12, 2026 Annual General Meeting were approved by shareholders on a poll.
Shareholders adopted the audited financial statements for the year ended December 31, 2025, with 440,149,560 votes in favor and only 1,020 against. All nominated directors, including Dr Dan Eldar, Dr Weiguo Su and Chief Financial Officer Johnny Cheng, were re-elected with approval levels generally above 93% of votes cast.
PricewaterhouseCoopers and PricewaterhouseCoopers Zhong Tian LLP were re-appointed as independent auditors. Shareholders also granted directors a general mandate to issue additional shares and a separate mandate to repurchase shares, and approved the adoption of the 2026 Share Option Scheme, which received approximately 90.2% of votes cast in favor.
HUTCHMED (China) Limited reports that all resolutions at its May 12, 2026 Annual General Meeting were approved by shareholders on a poll.
Shareholders adopted the audited financial statements for the year ended December 31, 2025, with 440,149,560 votes in favor and only 1,020 against. All nominated directors, including Dr Dan Eldar, Dr Weiguo Su and Chief Financial Officer Johnny Cheng, were re-elected with approval levels generally above 93% of votes cast.
PricewaterhouseCoopers and PricewaterhouseCoopers Zhong Tian LLP were re-appointed as independent auditors. Shareholders also granted directors a general mandate to issue additional shares and a separate mandate to repurchase shares, and approved the adoption of the 2026 Share Option Scheme, which received approximately 90.2% of votes cast in favor.
HUTCHMED (China) Limited has updated the market on its total voting rights. As at April 30, 2026, the company’s issued share capital consisted of 872,335,120 ordinary shares of US$0.10 each, with each share carrying one vote and no shares held in treasury.
The figure of 872,335,120 is the denominator shareholders can use to assess whether they must notify interests or changes in interests under the UK Financial Conduct Authority’s Disclosure Guidance and Transparency Rules. This share capital is equivalent to 872,335,120 depositary interests traded on AIM or 174,467,024 American depositary shares traded on Nasdaq.
HUTCHMED (China) Limited has updated the market on its total voting rights. As at April 30, 2026, the company’s issued share capital consisted of 872,335,120 ordinary shares of US$0.10 each, with each share carrying one vote and no shares held in treasury.
The figure of 872,335,120 is the denominator shareholders can use to assess whether they must notify interests or changes in interests under the UK Financial Conduct Authority’s Disclosure Guidance and Transparency Rules. This share capital is equivalent to 872,335,120 depositary interests traded on AIM or 174,467,024 American depositary shares traded on Nasdaq.
HUTCHMED (China) Limited reports that China’s National Medical Products Administration has accepted the New Drug Application for sovleplenib to treat adults with warm antibody autoimmune hemolytic anemia (wAIHA) who responded poorly to prior glucocorticoid therapy. The NDA has priority review status and Breakthrough Therapy Designation, reflecting its potential in a serious disease with limited options.
The filing is backed by the ESLIM-02 Phase II/III trial, where the Phase III segment met its primary endpoint of durable hemoglobin response. Earlier Phase II data in The Lancet Haematology showed hemoglobin benefits versus placebo and response rates up to 66.7% over 24 weeks, with a favorable safety profile. Sovleplenib is also in late-stage development for immune thrombocytopenia, where a separate NDA in China has been accepted with priority review.
HUTCHMED (China) Limited reports that China’s National Medical Products Administration has accepted the New Drug Application for sovleplenib to treat adults with warm antibody autoimmune hemolytic anemia (wAIHA) who responded poorly to prior glucocorticoid therapy. The NDA has priority review status and Breakthrough Therapy Designation, reflecting its potential in a serious disease with limited options.
The filing is backed by the ESLIM-02 Phase II/III trial, where the Phase III segment met its primary endpoint of durable hemoglobin response. Earlier Phase II data in The Lancet Haematology showed hemoglobin benefits versus placebo and response rates up to 66.7% over 24 weeks, with a favorable safety profile. Sovleplenib is also in late-stage development for immune thrombocytopenia, where a separate NDA in China has been accepted with priority review.
HUTCHMED (China) Limited is highlighting new oncology research that will be presented at the AACR Annual Meeting 2026 in San Diego from April 17-22, 2026. The presentations focus on its antibody-targeted therapy conjugate (ATTC) platform and combination regimens for difficult gastrointestinal cancers.
Preclinical data for HMPL-A580, a first-in-class PI3K/PIKK-EGFR ATTC, show potent and selective kinase inhibition with IC50 values around 1–10 nM and strong anti-tumor effects in EGFR-expressing models. In mouse xenograft models, weekly intravenous dosing at 1–10 mg/kg produced dose-dependent tumor growth inhibition and favorable pharmacokinetics in non-human primates.
Updated clinical data will also be presented from a multicenter Phase Ib/II trial of surufatinib plus sintilimab and capecitabine in metastatic small bowel and appendiceal cancers, and from an exploratory Phase II study combining surufatinib with gemcitabine and nab-paclitaxel in locally advanced or metastatic pancreatic ductal adenocarcinoma following induction therapy.
HUTCHMED (China) Limited is highlighting new oncology research that will be presented at the AACR Annual Meeting 2026 in San Diego from April 17-22, 2026. The presentations focus on its antibody-targeted therapy conjugate (ATTC) platform and combination regimens for difficult gastrointestinal cancers.
Preclinical data for HMPL-A580, a first-in-class PI3K/PIKK-EGFR ATTC, show potent and selective kinase inhibition with IC50 values around 1–10 nM and strong anti-tumor effects in EGFR-expressing models. In mouse xenograft models, weekly intravenous dosing at 1–10 mg/kg produced dose-dependent tumor growth inhibition and favorable pharmacokinetics in non-human primates.
Updated clinical data will also be presented from a multicenter Phase Ib/II trial of surufatinib plus sintilimab and capecitabine in metastatic small bowel and appendiceal cancers, and from an exploratory Phase II study combining surufatinib with gemcitabine and nab-paclitaxel in locally advanced or metastatic pancreatic ductal adenocarcinoma following induction therapy.